The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Its mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in three critical therapeutic areas: serious infectious disease care, cardiovascular care and surgery and perioperative care. 
The Medicines Company markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has two products in late stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. Its pipeline also includes a serine protease inhibitor, CU2010, in early-stage development.


Show more
Type
Public
HQ
Parsippany-Troy Hills, US
Founded
1996
Size (employees)
410 (est)
The Medicines Company was founded in 1996 and is headquartered in Parsippany-Troy Hills, US
Report incorrect company information

The Medicines Company Office Locations

The Medicines Company has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
8 Sylvan Way
Show all (1)
Report incorrect company information

The Medicines Company Financials and Metrics

The Medicines Company Financials

The Medicines Company's revenue was reported to be $44.79 m in FY, 2017
USD

Revenue (FY, 2017)

44.8 m

Net income (FY, 2017)

(708.4 m)

EBIT (FY, 2017)

(665.1 m)

Market capitalization (20-Apr-2018)

2.1 b

Cash (31-Dec-2017)

151.4 m
The Medicines Company's current market capitalization is $2.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.1 m1.3 m309 m167.8 m44.8 m

Revenue growth, %

(75%)23670%(46%)

General and administrative expense

319.2 m132.2 m

R&D expense

139.3 m138.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

90.5 m72.7 m50.3 m54.7 m37.6 m24.2 m18.7 m

Cost of goods sold

37 m18.8 m15.2 m

Gross profit

53.5 m31.5 m39.5 m

Gross profit Margin, %

59%63%72%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

376.7 m370.7 m373.2 m541.8 m151.4 m

Accounts Receivable

2 k14.7 m

Inventories

12.6 m16 m20 m70.9 m5.6 m

Current Assets

591.4 m657 m832.9 m654 m563.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

462.4 m378.4 m368.3 m356.2 m607.1 m462.7 m508.8 m430.2 m644.2 m600.4 m436.7 m202.4 m

Inventories

91.5 m86 m86.3 m75.2 m127.4 m127.8 m114.3 m68.5 m74.1 m70.7 m71.7 m71.4 m

Current Assets

683.7 m595.7 m603.1 m584.9 m881.7 m660.4 m687.3 m560.8 m789.3 m717.4 m546.3 m436 m

Goodwill

186.8 m257.8 m284.8 m285.3 m314.1 m313.5 m313.2 m289.4 m255.6 m255.6 m255.6 m255.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

15.3 m(32.3 m)(352.7 m)(119.2 m)(708.4 m)

Depreciation and Amortization

32.2 m34.4 m34.8 m31 m22 m

Inventories

39 k(3.6 m)(5.3 m)569 k

Accounts Payable

(1.3 m)(6.9 m)16.4 m(7.4 m)(17.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

14.2 m(5 m)(10.2 m)(27 m)5 m(41.5 m)(146.7 m)(92.5 m)182.4 m(86.3 m)(102.7 m)

Depreciation and Amortization

20 m7.9 m17 m26 m7.6 m14.9 m24.2 m

Inventories

(15.1 m)1.1 m1.1 m12.1 m(46 m)(54.6 m)(57.8 m)68.5 m74.1 m70.7 m

Accounts Payable

6 m(19.6 m)(19.4 m)(18.5 m)(6.1 m)(2.2 m)(2.1 m)15.5 m26.7 m18.7 m17.5 m
USDY, 2017

Revenue/Employee

109.2 k

Financial Leverage

35 x
Show all financial metrics
Report incorrect company information